Abstracts Archive - Page 1667 of 2607 - ACR Meeting Abstracts

Abstract Number: 1014 • 2016 ACR/ARHP Annual Meeting
Juvenile Dermatomyositis: What Comes Next?
Christina A. Boros¹, Liza J. McCann², Nicola Ambrose³, Mario Cortina-Borja⁴, Stephanie Simou⁵, Clarissa Pilkington⁶ and Lucy R Wedderburn⁷, ¹UCL INstiute of Chuld Health, London, United Kingdom, ²Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ³Department of Vascular Sciences, National Heart and Lung Institute, Imperial College, London, United Kingdom, ⁴Population, PLociy and Practice, UCL Institute of Child Health, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁷Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Few studies describe the natural course and long term outcomes of myositis in childhood in large, prospectively-followed patient cohorts, treated in the modern era.…
Abstract Number: 1015 • 2016 ACR/ARHP Annual Meeting
Pro-Inflammatory Cytokines Produced By Different Subsets of Peripheral Blood Mononuclear Cells Are Associated with Ro52/TRIM21 Deficiency in Patients with Inflammatory Myopathies
Ana Barrera-Vargas¹, Angeles Shunashy Galindo-Feria², Diana Gómez-Martín¹, Javier Merayo-Chalico¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, heterogeneous autoimmune diseases of unknown etiology. Different physiopathogenic mechanisms have been proposed, including the production…
Abstract Number: 1016 • 2016 ACR/ARHP Annual Meeting
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Baptiste Hervier^1,2, Samra Ouaras², Laurent Gilardin³, Hanane Ouakrim⁴, Damien Amelin⁵, Fleur Cohen⁶, Yurdagul Uzunhan⁷, Yves Allenbach¹, Anne Bourgarit-Durand⁸, Olivier Benveniste⁹ and Vincent Vieillard¹⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²CIMI Paris, UMR-S 1135, INSERM & UPMC, Paris, France, ³Internal Medicine, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁴INSERM UMR-S 1138, Centre des cordeliers & APHP, Cochin Hospital, Laboratory of Pathology, Paris, France, ⁵Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁸CHU Bondy, Bondy, France, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰P&M Curie university, INSERM 543, Paris, France
Background/Purpose: Antisynthetase syndrome (ARS) is an inflammatory myopathy (IM) commonly associated to interstitial lung disease (ILD) and different anti-tRNA-synthetase autoantibodies. The immune mechanisms leading to…
Abstract Number: 1017 • 2016 ACR/ARHP Annual Meeting
Statistical Simulation Using Data from the Foundation for the National Institute of Health/Osteoarthritis Initiative Biomarkers Consortium to Evaluate the Clinical Utility of Prognostic Knee Osteoarthritis Biomarkers in Designing a Knee Osteoarthritis Clinical Trial
Sheng Feng¹, Zheng (Roger) Liu², Feng Hong¹, Jeroen Medema¹, Rajesh Kamath¹ and Marc C. Levesque¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Development of disease-modifying osteoarthritis drugs (DMOADs) for knee osteoarthritis (OA) has been challenging, partially owing to lack of prognostic biomarkers. Our objective was to…
Abstract Number: 1018 • 2016 ACR/ARHP Annual Meeting
Dietary Intake of Fiber and Risk of Knee Osteoarthritis
Zhaoli (Joy) Dai¹, Jingbo Niu¹, Yuqing Zhang², Paul Jacques³ and David T. Felson⁴, ¹Clinical epidemiology research and training unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ³Jean Mayer USDA Human Nutrition Research Center on Aging and Friedman School of Nutrition Science and Policy, Tufts University, Boston, Boston, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Dietary fiber reduced risks of metabolic diseases in part by reducing systemic inflammation and body weight. These factors are both likely to contribute to…
Abstract Number: 1019 • 2016 ACR/ARHP Annual Meeting
The Impact of Hip and Knee Osteoarthritis on the Subsequent Risk of Incident Diabetes: A Population-Based Cohort Study
Tetyana Kendzerska^1,2,3, Lauren King¹, Ruth Croxford², Ian Stanaitis³, Angela Wall³ and Gillian Hawker^1,2,3, ¹University of Toronto, Toronto, ON, Canada, ²Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ³Women's College Research Institute/Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) and diabetes commonly co-occur. Potential explanations include common risk factors (aging, obesity) and the effects of OA-related functional limitations on diabetes risk…
Abstract Number: 1020 • 2016 ACR/ARHP Annual Meeting
Risk Factors Can Classify Individuals Who Develop Accelerated Knee Osteoarthritis
Jeffrey Driban¹, Timothy E. McAlindon², Mamta Amin³, Lori Lyn Price⁴, Charles B. Eaton⁵, Julie Davis⁶, Bing Lu⁷, Grace H. Lo⁸, Jeffrey Duryea⁹ and Mary Barbe¹⁰, ¹Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA, ³Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA, ⁴Clinical Care Research, Tufts Medical Center, Boston, MA, ⁵Family Medicine and Community Health( Epidemiology), Alpert Medical School of Brown University, Pawtucket, RI, ⁶Rheumatology, Tufts Medical Center, Boston, MA, ⁷Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ⁸Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ⁹Radiology, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA, ¹⁰Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Accelerated knee osteoarthritis (KOA) is a painful disorder and associated with several risk factors: greater age, greater body mass index (BMI), static knee alignment,…
Abstract Number: 1021 • 2016 ACR/ARHP Annual Meeting
Maintaining Sufficient Serum Vitamin D Levels over 2 Years Is Associated with Reduced Knee Structural and Symptomatic Changes in Patients with Knee Osteoarthritis
Shuang Zheng¹, Xingzhong Jin¹, Flavia M Cicuttini², Xia Wang¹, Zhaohua Zhu¹, Anita E Wluka³, Weiyu Han¹, Tania Winzenberg¹, Leigh Blizzard¹, Graeme Jones⁴ and Changhai Ding⁴, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia, ³Australia, Armadale, Australia, ⁴Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
Background/Purpose: To examine whether those maintaining sufficient serum vitamin D levels have reduced knee structural changes and symptomatic improvement compared with those not maintaining sufficient…
Abstract Number: 1022 • 2016 ACR/ARHP Annual Meeting
The Risk of Symptomatic Knee Osteoarthritis after Arthroscopic Meniscus Repair Vs Partial Meniscectomy Vs the General Population
Martin Englund¹, Aleksandra Turkiewicz², Dan Bergkvist³, Paul Neuman⁴ and Fredrik Persson⁴, ¹Clinical Epidemiology Unit, Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Orthopedics, Lund, Sweden, ²Clinical Epidemiology Unit, Lund University, Department of Clinical Sciences Lund, Orthopedics, Lund, Sweden, ³Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁴Lund University, Skåne University Hospital, Orthopedics, Malmoe, Sweden
Background/Purpose: Traumatic meniscus injury is associated with increased risk of developing knee osteoarthritis (OA). The purpose of meniscus repair, beyond short time symptom relief and…
Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
F Cosman¹, DB Crittenden², JD Adachi³, N Binkley⁴, E Czerwinski⁵, S Ferrari⁶, LC Hofbauer⁷, E Lau⁸, EM Lewiecki⁹, A Miyauchi¹⁰, CAF Zerbini¹¹, CE Milmont², L Chen², J Maddox², PD Meisner¹², C Libanati¹² and A Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, ⁵Krakow Medical Center, Krakow, Poland, ⁶Geneva University Hospital, Geneva, Switzerland, ⁷Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, ⁸Center for Clinical and Basic Research, Hong Kong, China, ⁹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹⁰Miyauchi Medical Center, Osaka, Japan, ¹¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹²UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…
Abstract Number: 1024 • 2016 ACR/ARHP Annual Meeting
Superior Gains in Bone Mineral Density and Estimated Strength at the Hip for Romosozumab Compared with Teriparatide in Women with Postmenopausal Osteoporosis Transitioning from Bisphosphonate Therapy: Results of a Phase 3, Open-Label Clinical Trial
B Langdahl¹, C Libanati², DB Crittenden³, MA Bolognese⁴, JP Brown⁵, NS Daizadeh³, K Engelke⁶, HK Genant⁷, S Goemaere⁸, Lars Hyldstrup⁹, E Jodar-Gimeno¹⁰, TM Keaveny¹¹, D Kendler¹², P Lakatos¹³, J Maddox³, J Malouf¹⁴, FE Massari¹⁵, JF Molina¹⁶, MR Ulla¹⁷ and A Grauer³, ¹Aarhus University Hospital, Aarhus, Denmark, ²UCB Pharma, Brussels, Belgium, ³Amgen Inc., Thousand Oaks, CA, ⁴Bethesda Health Research Center, Bethesda, MD, ⁵Laval University and CHU de Québec (CHUL) Research Centre, Quebec City, QC, Canada, ⁶BioClinica Inc., Hamburg, Germany, ⁷Department of Radiology, University of California San Francisco, San Francisco, CA, ⁸Ghent University Hospital, Gent, Belgium, ⁹Hvidovre University Hospital, Hvidovre, Denmark, ¹⁰Servicio de Endocrinología, Hospital Universitario Quirón, Madrid, Spain, ¹¹University of California at Berkeley, Berkeley, CA, ¹²University of British Columbia, Vancouver, BC, Canada, ¹³Department of Medicine, Semmelweis University, Budapest, Hungary, ¹⁴Universitat Autònoma de Barcelona, Barcelona, Spain, ¹⁵Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ¹⁶Reumalab Centro Integral de Reumatologia, Medellin, Colombia, ¹⁷Instituto Latinoamericano de Investigaciones Médicas, Córdoba, Argentina
Background/Purpose: STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or teriparatide for 12 months in women with postmenopausal osteoporosis transitioning from…
Abstract Number: 1025 • 2016 ACR/ARHP Annual Meeting
Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Masao Yukioka⁴, Takaaki Noguchi⁵ and Hideki Yoshikawa⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Orthopedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁶Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: The efficacies of switching bisphosphonate (BP) to denosumab (DMAb), an anti-RANKL antibody which strongly inhibits bone resorption, or daily teriparatide (TPTD), a bone anabolic…
Abstract Number: 1026 • 2016 ACR/ARHP Annual Meeting
Morphea-like Skin Lesions Reported in the Phase 3 Long-Term Odanacatib Fracture Trial and Extension in Postmenopausal Women with Osteoporosis
Kenneth G. Saag¹, Tobie de Villiers², Peter Alexandersen³, Heidi Jacobe⁴, Carrie Kovarik⁵, Victoria P. Werth⁶, Albert Leung⁷, Avani Desai-Merchant⁸, Julie Mattaliano⁸ and Deborah Gurner⁸, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, Cape Town, South Africa, ³Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ⁴Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA, Philadelphia, PA, ⁷Formerly Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ⁸Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ
Background/Purpose: LOFT was a double-blind, placebo-controlled trial. Women ≥65 years with total hip (TH) or femoral neck (FN) bone mineral density (BMD) T-score ≤-2.5, or…
Abstract Number: 1027 • 2016 ACR/ARHP Annual Meeting
Odanacatib Efficacy and Safety in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial
Michael R. McClung¹, Bente Langdahl², Socrates Papapoulos³, Kenneth G. Saag⁴, Henry Bone⁵, Douglas P. Kiel⁶, Kurt Lippuner⁷, Toshitaka Nakamura⁸, Ian Reid⁹, Norman Heyden¹⁰, Carolyn DaSilva¹⁰, Boyd B. Scott¹⁰, Rachid Massaad¹¹, Keith D. Kaufman¹⁰, S. Aubrey Stoch¹⁰, Arthur Santora¹⁰, Deborah Gurner¹⁰ and Antonio Lombardi¹⁰, ¹Oregon Osteoporosis Center, Portland, OR, USA, Portland, OR, ²Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ³Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Michigan Bone & Mineral Clinic, Detroit, MI, USA and The Osteoporosis Center at St. Luke's Hospital, Chesterfield, MO, USA, Detroit, MI, ⁶Institute for Aging Research, Institute for Aging Research, Hebrew Senior Life, Harvard Medical School, Boston, MA, USA, Boston, MA, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸University of Occupational and Environmental Health, Fukuoka, Japan, Fukuoaka, Japan, ⁹University of Auckland, Auckland, New Zealand, Auckland, New Zealand, ¹⁰Merck & Co., Inc., Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Long-Term Odanacatib Fracture Trial [Women 65 years of age with BMD T-score ≤–2.5 at total hip (TH) or femoral neck (FN), or with radiographic…
Abstract Number: 1028 • 2016 ACR/ARHP Annual Meeting
Discontinuation of Denosumab and Associated Vertebral Fracture Incidence: Analysis from a Phase 3 Placebo-Controlled Study of Denosumab and Its Open-Label Extension
Jacques P Brown¹, S Ferrari², N Gilchrist³, Jens-Erik Beck Jensen⁴, N Pannacciulli⁵, Chris Recknor⁶, Christian Roux⁷, Shawna Smith⁵, Ove Törring⁸, Ivo Valter⁹, Rachel B Wagman⁵, A Wang⁵ and SR Cummings¹⁰, ¹Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ²Geneva University Hospital, Geneva, Switzerland, ³The Princess Margaret Hospital, Christchurch, New Zealand, ⁴Hvidovre University Hospital, Hvidovre, Denmark, ⁵Amgen Inc., Thousand Oaks, CA, ⁶United Osteoporosis Centers, Gainesville, GA, ⁷Paris Descartes University, Paris, France, ⁸Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, ⁹Center for Clinical and Basic Research, Tallinn, Estonia, ¹⁰SFCC, CPMC Research Institute & UCSF, San Francisco, CA
Background/Purpose: Denosumab (DMAb) treatment has been shown to decrease fracture (Fx) risk. Unlike bisphosphonates, DMAb is a monoclonal antibody against RANKL. Discontinuation is characterized by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].